Medtronic launches improved delivery system for minimally invasive
treatment of thoracic aortic aneurysms
14 October 2009
Medtronic, Inc. (NYSE: MDT) has announced European approval and the
international launch of the Captivia Delivery System for the Valiant
Thoracic Stent Graft, a minimally invasive treatment for aneurysms and
other lesions of the thoracic aorta.
The Captivia Delivery System features tip capture for enhanced
control of the Valiant thoracic stent graft during deployment and a
hydrophilic coating applied to the graft cover to facilitate iliac
access and delivery through patients’ vasculature.
The new Valiant Captivia system enables physicians to treat a wide
range of anatomies with a highly conformable stent graft, with accuracy
and ease of delivery to achieve optimal clinical results.
Both the Valiant Thoracic Stent Graft and Captivia Delivery System
are investigational in the United States, where their use is limited to
clinical trials approved by the US FDA.
Prof. Giovanni Torsello, chief of vascular surgery at St. Franziskus-Hospital
in Muenster, Germany, performed the first Valiant Thoracic Stent Graft
implantation with the Captivia Delivery System.
“The Captivia Delivery System’s tip capture feature provides
excellent control of the stent graft during deployment, which is
critically important when treating lesions in the thoracic aorta,” Prof.
Torsello said. “Its hydrophilic coating has also made a significant
improvement in stent graft delivery. These added features will provide
greater confidence in physicians’ ability to treat these very
Indicated for the treatment of a variety of thoracic aortic lesions,
in four years of clinical experience, more than 15,000 patients
worldwide have received the Valiant Thoracic Stent Graft.
“Given the widespread acceptance and growing use of our Valiant
Thoracic Stent Graft, the Captivia Delivery System represents an
enhancement that provides physicians with outstanding ease of access and
delivery, as well as deployment accuracy and control,” said Tony Semedo,
vice president and general manager of Endovascular Innovations, part of
the CardioVascular business at Medtronic. “Combined with the Valiant
Thoracic Stent Graft, which retains its hallmark attribute of
conformability, the new system will expand endovascular treatment to
more patients with complex aortic disease.”
Bookmark this page